If you want a TL;DR of the biggest upcoming home movie and TV show releases, look no further than the list above. We keep it updated and change out the featured items regularly. Below, you'll find ...

A regulatory decision is expected by July 30, 2025. The US Food and Drug Administration (FDA) has accepted for review the resubmitted biologics license application for odronextamab to treat ...

When your doctor talks to you about your B-cell lymphoma, they'll tell you what type you have. It's an important piece of info to get, because each type of this cancer acts differently and has its ...

Pull requests help you collaborate on code with other people. As pull requests are created, they’ll appear here in a searchable and filterable list. To get started, you should create a pull request.

Evidence that smoking causes non-Hodgkin’s lymphoma is mixed. However, smoking might create molecules that could prevent the destruction of cancerous cells. In general, smoking increases the ...

LUBBOCK, Texas (KCBD) - “We like the environment, the schools and everything. I work here as well and it’s been good, until now. Then we have this situation going on.” Estela and her family moved to ...

Regeneron Pharmaceuticals said the Food and Drug Administration has accepted for review its resubmitted application seeking approval of odronextamab for certain patients with one of the most ...

Odronextamab is approved as Ordspono in the European Union for the treatment of R/R FL or diffuse large B-cell lymphoma (DLBCL). The views and opinions expressed herein are the views and opinions ...

Regeneron, which is seeking an FDA nod for odronextamab in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy, said the agency set a target action date of July 30 ...

The FDA has accepted the biologics licensing application (BLA) resubmission for odronextamab, a potential treatment for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. The ...